文献速递白血病

t(8;21)急性髓系白血病的可测量残留病监测:AML研究组结果

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
PubMed 文献 · Blood · 2019-01-01

该研究对155例强化治疗的RUNX1-RUNX1T1阳性AML患者进行骨髓和外周血连续MRD监测,采用灵敏度达10^-6的qRT-PCR assay。结果显示治疗后MR2.5和MR3.0与复发风险降低相关,治疗结束后骨髓和外周血MRD阴性是独立的有利预后因素,连续qRT-PCR可预测多数患者复发。

要点

  • 第1周期后MR2.5和第2周期后MR3.0与复发风险降低显著相关。
  • 治疗结束后骨髓和外周血MRD阴性均为独立有利预后因素。
  • 随访中qRT-PCR可预测复发,骨髓阈值150、外周血阈值50 RUNX1-RUNX1T1转录本水平。

核心结论

  • RUNX1-RUNX1T1转录本水平动态监测可评估t(8;21)AML预后,治疗结束后骨髓和外周血MRD阴性为独立有利因素。

研究设计与样本

  • 对155例强化治疗的RUNX1-RUNX1T1阳性AML患者,连续采集骨髓和外周血,采用灵敏度达10^-6的qRT-PCR assay监测MRD。

主要发现

  • 第1周期后MR2.5与复发风险降低相关(P=.034),第2周期后MR3.0与复发风险降低相关(P=.028)。
  • 治疗结束后骨髓和外周血MRD阴性者的4年累积复发率分别为17% vs 36%(P=.021)和23% vs 55%(P=.001)。
  • 治疗结束后骨髓和外周血MRD阴性者的4年总生存率分别为93% vs 70%(P=.007)和87% vs 47%(P<.0001)。
  • 随访中连续qRT-PCR可预测复发:骨髓RUNX1-RUNX1T1转录本水平超过150时预测77%患者复发,外周血超过50时预测84%患者复发。
  • KIT突变预测较低完全缓解率和较差结局,但其预后影响被治疗期间RUNX1-RUNX1T1转录本水平所超越。

关键数值与推荐

  • 第1周期后MR2.5(>2.5 log下降)与复发风险降低显著相关(P=.034)。
  • 第2周期后MR3.0与复发风险降低显著相关(P=.028)。
  • 治疗结束后骨髓MRD阴性4年累积复发17% vs 36%(P=.021),4年总生存93% vs 70%(P=.007)。
  • 治疗结束后外周血MRD阴性4年累积复发23% vs 55%(P=.001),4年总生存87% vs 47%(P<.0001)。
  • 随访中骨髓RUNX1-RUNX1T1转录本水平>150预测77%复发,外周血>50预测84%复发。

临床怎么用

  • 对RUNX1-RUNX1T1阳性AML患者,应在治疗第1、2周期后评估转录本水平下降幅度。
  • 治疗结束后应检测骨髓和外周血MRD状态以判断预后。
  • 治疗结束后1年内几乎所有复发发生,分子到形态学复发潜伏期很短,需短间隔MRD监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We performed serial measurable residual disease (MRD) monitoring in bone marrow (BM) and peripheral blood (PB) samples of 155 intensively treated patients with RUNX1-RUNX1T1+ AML, using a qRT-PC-based assay with a sensitivity of up to 10-6. We assessed both reduction of RUNX1-RUNX1T1 transcript levels (TLs) and achievement of MRD negativity (MRD-) for impact on prognosis. Achievement of MR2.5 (>2.5 log reduction) after treatment cycle 1 and achievement of MR3.0 after treatment cycle 2 were significantly associated with a reduced risk of relapse (P = .034 and P = .028, respectively). After completion of therapy, achievement of MRD- in both BM and PB was an independent, favorable prognostic factor in cumulative incidence of relapse (4-year cumulative incidence relapse: BM, 17% vs 36%, P = .021; PB, 23% vs 55%, P = .001) and overall survival (4-year overall survival rate BM, 93% vs 70%, P = .007; PB, 87% vs 47%, P < .0001). Finally, during follow-up, serial qRT-PCR analyses allowed prediction of relapse in 77% of patients exceeding a cutoff value of 150 RUNX1-RUNX1T1 TLs in BM, and in 84% of patients exceeding a value of 50 RUNX1-RUNX1T1 TLs in PB. The KIT mutation was a significant factor predicting a lower CR rate and inferior outcome, but its prognostic impact was outweighed by RUNX1-RUNX1T1 TLs during treatment. Virtually all relapses occurred within 1 year after the end of treatment, with a very short latency from molecular to morphologic relapse, necessitating MRD assessment at short intervals during this time period. Based on our data, we propose a refined practical guideline for MRD assessment in RUNX1-RUNX1T1+ AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Rücker FG, Agrawal M, Corbacioglu A, et al. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood. 2019. PMID: 31554635. doi:10.1182/blood.2019001425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。